908 Devices Inc(MASS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.94 | Insider Own | 20.91% | Shs Outstand | 38.1M | Perf Week | 9.07% |
| Market Cap | 0.53B | Forward P/E | - | EPS next Y | 49.65% | Insider Trans | -10% | Shs Float | 32.7M | Perf Month | 8.61% |
| Enterprise Value | 0.43B | PEG | - | EPS next Q | -0.15 | Inst Own | 67.95% | Short Float | 8.29% | Perf Quarter | 68.46% |
| Income | -0.03B | P/S | 8.74 | EPS this Y | -494.89% | Inst Trans | 1.9% | Short Ratio | 6.38 | Perf Half Y | 98% |
| Sales | 0.06B | P/B | 3.86 | EPS next 5Y | -15.07% | ROA | -17.61% | Short Interest | 2.71M | Perf YTD | 145.14% |
| Book/sh | 3.33 | P/C | 5.17 | EPS past 3/5Y | 1.43% -16.61% | ROE | -24.88% | 52W High | -3.58% ($13.35) | Perf Year | 61.08% |
| Cash/sh | 2.49 | P/FCF | 1085.63 | Sales past 3/5Y | 6.25% 15.88% | ROIC | -26.45% | 52W Low | 156.12% ($5.03) | Perf 3Y | 150.39% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 56.39% | Gross Margin | 48.76% | Volatility(W/M) | 5.1% 5.16% | Perf 5Y | -60.44% |
| Dividend TTM | - | EV/Sales | 7.12 | Sales Y/Y TTM | 0.72% | Oper. Margin | -35.42% | ATR (14) | 0.6 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.38 | EPS Q/Q | 14.99% | Profit Margin | -56.68% | RSI (14) | 64.91 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.67 | Sales Q/Q | 23.31% | SMA20 | 7.67% ($11.95) | Beta | 0.64 | Target Price | $13.38 |
| Payout | - | Debt/Eq | 0.03 | Earnings | 2026/11/10 | SMA50 | 15.43% ($11.15) | Rel Volume | 0.7 | Prev Close | $12.36 |
| Employees | 172 | LT Debt/Eq | 0.03 | EPS/Sales Surpr. | -125.35% 4.55% | SMA200 | 55.06% ($8.3) | Avg Volume(3M) | 0.42M | Price | $12.87 |
| IPO | 2020/12/18 | Option/Short | Yes/Yes | Trades | 2609 | Volume | 298,890 | Change | 4.13% |
🔬 908 Devices (MASS) is a U.S. medical device and analytical instrumentation company that develops handheld and compact mass spectrometry-based equipment for detecting chemical and biological substances. Its strength lies in bringing precision analysis—which has traditionally been confined to large laboratories—into the field, enabling rapid substance identification at security, industrial, and life sciences sites.
Over the past 1 year, on the higher side
4% below its 1-year high.
Traded less than usual. That is 70% of its average volume.
Next earnings report: November 10
12 days to go.
MASS has a sound balance sheet but weak earning power
Of every $100 in sales, $35.42 is lost.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -494.9% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $874. Peers typically go for $343.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -60.4%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 68.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #55 of 142 in the industry
Based on market cap of $532M.
FAQ
What kind of company is MASS?
MASS belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of MASS?
The market cap of MASS is approximately $532M, ranking 3,107 within its sector.
What is the 52-week high and low for MASS?
MASS has recorded a 52-week high of $13.35 and a low of $5.03.
